SURGICAL SCIENCE SWEDEN

Research SURGICAL SCIENCE SWEDEN (4P41) on Bullrun: market cap EUR 239.52M, P/E 29.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 239.52M; P/E is 29.3.

Peer valuation comparison

Latest P/E is 29.34x versus a Healthcare sector median of 24.46x (19.9% above).

Latest P/E is 29.34x versus a Sweden median of 18.57x (58.0% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 992.34MSEK 66.82MSEK 30.45M66.3%1.31SEK 616.43MSEK 56.40MSEK 4.27B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 239.52M29.3n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About SURGICAL SCIENCE SWEDEN

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is SURGICAL SCIENCE SWEDEN's market cap?

SURGICAL SCIENCE SWEDEN's market capitalization is EUR 239.52M.

What is SURGICAL SCIENCE SWEDEN's P/E ratio?

SURGICAL SCIENCE SWEDEN's price-to-earnings (P/E) ratio is 29.3.

What does SURGICAL SCIENCE SWEDEN do?

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally.